Homology Medicines Stock Forecast, Price & News

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FIXX shares have decreased by 41.0% and is now trading at $10.57.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Homology Medicines.

Homology Medicines is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Homology Medicines.

Homology Medicines Inc (NASDAQ:FIXX) posted its earnings results on Monday, August, 10th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.04. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.47 million. Homology Medicines had a negative net margin of 5,764.94% and a negative return on equity of 53.10%.
View Homology Medicines' earnings history.

7 Wall Street analysts have issued 12-month price objectives for Homology Medicines' stock. Their forecasts range from $27.00 to $34.00. On average, they expect Homology Medicines' stock price to reach $30.43 in the next twelve months. This suggests a possible upside of 187.9% from the stock's current price.
View analysts' price targets for Homology Medicines.

Homology Medicines saw a decrease in short interest in September. As of September 30th, there was short interest totaling 4,430,000 shares, a decrease of 19.6% from the September 15th total of 5,510,000 shares. Based on an average daily trading volume, of 504,000 shares, the short-interest ratio is currently 8.8 days. Approximately 15.0% of the company's shares are short sold.
View Homology Medicines' Short Interest.

Some companies that are related to Homology Medicines include Amarin (AMRN), Akcea Therapeutics (AKCA), uniQure (QURE), Zymeworks (ZYME), Kura Oncology (KURA), Viela Bio (VIE), Y-mAbs Therapeutics (YMAB), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Dicerna Pharmaceuticals (DRNA) and Cryoport (CYRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include American Investment Services Inc. (0.08%), WINTON GROUP Ltd (0.05%), DekaBank Deutsche Girozentrale (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am and W Bradford Smith.
View institutional ownership trends for Homology Medicines.

FIXX stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, James E Flynn, Timothy P Kelly, and W Bradford Smith.
View insider buying and selling activity for Homology Medicines.

FIXX stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, American Investment Services Inc., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Homology Medicines.

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FIXX stock can currently be purchased for approximately $10.57.

Homology Medicines has a market capitalization of $477.95 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.

The official website for Homology Medicines is www.homologymedicines.com.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.